M. Ferrante

Gastroenterology · 2003–2020

A researcher in the Science corpus: 10 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom M. Ferrante trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Ian T. Jolliffe

Papers from M. Ferrante's perspective

Ordered by how strongly the researchers M. Ferrante trusts endorse each paper. Same corpus, a different order for every researcher.

1. ImageNet classification with deep convolutional neural networks
2. Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift (International Conference on Machine Learning)
3. Introduction to the theory of neural computation
4. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review (American Journal of Gastroenterology)
5. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. (Health Economics)
6. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives (Gut)
7. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. (New England Journal of Medicine)
8. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. (Gastrointestinal Endoscopy)
9. Principal Component Analysis
10. Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists

Their papers

• A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis (2013) — 1,715 citations
• Electronic nose based discrimination of a perfumery compound in a fragrance (2003) — 82 citations
• Ulcerative colitis (2020) — 1,082 citations
• Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI (2019) — 309 citations
• Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. (2016) — 887 citations
• Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. (2015) — 847 citations
• European evidence based consensus for endoscopy in inflammatory bowel disease. (2013) — 820 citations
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease (2012) — 810 citations
• Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. (2011) — 3,443 citations
• Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease (2009) — 695 citations